文献速递类风湿关节炎

类风湿关节炎患者外周血免疫表型多样性及其对治疗反应的影响

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
PubMed 文献 · Ann Rheum Dis · 2025-01-02

研究对超过500例未使用过生物/靶向合成改善病情抗风湿药(b/tsDMARDs)的类风湿关节炎(RA)患者行流式细胞术免疫表型分析并分群,评估各靶向治疗的反应,另用183例同类患者验证。RA可分为5个集群,其中2个集群与对照相比具有独特表型,特征为再表达CD45RA的CD4+效应记忆T细胞显著增加;不同b/tsDMARDs在各集群中的疗效不同。使用「预期」b/tsDMARDs组的26周缓解率(39.9% vs 24.6%,p=0.0004)和低疾病活动度达标率(80.8% vs 60.2%,p<0.0001)均高于「非预期」组,验证队列中预期组缓解率亦更高(p=0.0021)。

要点

  • RA患者外周血免疫表型可分为5个集群,其中2个集群与对照相比表现独特,特征为再表达CD45RA的CD4+效应记忆T细胞显著增加。
  • 不同b/tsDMARDs在各免疫表型集群中的疗效不同。
  • 预期组26周缓解率39.9% vs 非预期组24.6%(p=0.0004),低疾病活动度达标率80.8% vs 60.2%(p<0.0001)。

核心结论

  • RA患者存在外周血免疫表型多样性,基于此的分层可能有助于选择b/tsDMARDs,研究结果为理解RA异质性和基于分子机制的治疗策略提供了线索。

研究设计与样本

  • 对超过500例未使用过b/tsDMARDs的RA患者行流式细胞术免疫表型分析并分群,评估各靶向治疗的反应,另用183例未使用过b/tsDMARDs的RA患者作为验证队列。

主要发现

  • RA患者被分为5个集群,其中2个集群与对照相比具有独特RA表型,特征为再表达CD45RA的CD4+效应记忆T细胞显著增加。
  • 不同b/tsDMARDs在各集群中的有效性不同;使用「预期」b/tsDMARDs组26周缓解率为39.9%,「非预期」组为24.6%(p=0.0004)。
  • 「预期」组低疾病活动度达标率为80.8%,「非预期」组为60.2%(p<0.0001)。
  • 轨迹分析显示「非预期」组26周疾病活动度受基线临床疾病活动指数影响,而「预期」组不受此影响。
  • 不同分子靶向治疗对各免疫细胞亚群比例的影响不同;验证队列183例按b/tsDMARDs使用分为预期/非预期组后,预期组缓解率更高(p=0.0021)。

局限性

  • 原文提到需要进一步研究:结论称研究结果为基于分子机制的治疗策略提供线索,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Considering the diverse aetiologies and immunodysregulatory statuses observed in each patient with rheumatoid arthritis (RA), stratification based on peripheral blood immunophenotyping holds the potential to enhance therapeutic responses to molecular targeted therapies, biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). METHODS: Immunophenotype analysis was conducted on a cohort of over 500 b/tsDMARDs-naïve patients using flow cytometry. Patients with RA were stratified based on their immunophenotypes, and the treatment response to each targeted therapy was evaluated. Validation was performed using an additional cohort of 183 b/tsDMARDs-naïve patients with RA. RESULTS: Patients with RA were stratified into five clusters, two of which exhibited distinct RA phenotypes compared with controls, characterised by significant increases in CD4+ effector memory T cells re-expressing CD45RA. Notably, the effectiveness of different b/tsDMARDs varied across clusters. The group using promising b/tsDMARDs was labelled as 'expected' whereas the 'non-expected' group comprised those using others. The expected group outperformed the non-expected group with higher 26-week remission rates (39.9% vs 24.6%, p=0.0004) and low disease activity achievement (80.8% vs 60.2%, p<0.0001). Trajectory analysis showed the non-expected group's 26-week disease activity was influenced by Clinical Disease Activity Index at baseline unlike the expected group. Additionally, different molecular targeted therapies influenced the proportions of each immune cell subset variably. To validate, immunophenotyping was performed on a validation cohort. When 183 cases were grouped based on their b/tsDMARDs usage into expected/non-expected groups, the expected group had a higher remission rate (p=0.0021), further confirming the observed trend. CONCLUSION: Our findings offer valuable insights into the diversity of RA and potential therapeutic strategies grounded in the molecular underpinnings.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kubo S, Miyazaki Y, Nishino T, et al. Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness. Ann Rheum Dis. 2025. PMID: 39919895. doi:10.1136/ard-2024-226228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。